Table 4: Natural Therapeutic Interventions and Prevention of Recurrence of Breast Cancer
Vitamin
supplementstaken the first six months after treatment resulted in lower recurrence and 18% reduced risk of mortality. The authors stated: “Our results do not support the current recommendation that breast cancer patients should avoid use of vitamin supplements.”1 |
Breast cancer survivors with serum
vitamin Dconcentrations at 55 nmol/L had a 1.55 times longer disease-free survival than those with 35 nm/L concentration.2 However, this was not seen in the WHEL trial where no relation between vitamin D and breast cancer recurrence was found.3 |
There is a (nonsignificant) lower risk of recurrence and disease-related mortality among those who self-reported using
vitamin C and Efor three years posttreatment (vitamin E nearly halved the risk.)4 |
Increased
green teaconsumption (more than three cups a day) was inversely associated with breast cancer recurrence (pooled RR = 0.73, 95% CI: 0.56–0.96) in a meta-analysis of 5716 cases.5 |
Black cohoshlengthens disease-free survival among 18,861 patients observed for 3.6 years. After 2 years following initial diagnosis, 14% of the control group had developed a recurrence, while the black cohosh extract group didn’t reach this proportion until after 6.5 years.6 However, black cohosh was found to increase the risk of lung metastasis in HER2-expressing transgenic mice. Caution in HER2+ patients is advised.7 |
A pilot study evaluated the survival of patients with various types of end-stage cancer including breast. 76% of those who received supplements of
coenzyme Q(10) and a mixture of other antioxidants(e.g. vitamin C, selenium, folic acid and beta-carotene) survived longer than predicted among the treatment group; on average, surviving 5 more months than the control group.8 |
The disease-free survival was increased from 84% to 100% when
PSK(extract from Coriolus versicolor) was added to biannual chemotherapy × 5 years. They studied 134 randomly selected breast cancer survivors who were HLAB40+. The benefit was not apparent among those whose tumors were HLAB40−.9 |
Daily administration of
melatoninsignificantly increased the survival time of tumor-bearing animals. This is only recommended for those with ER+ tumor history.10 |
| From these studies, I might recommend that a post-treatment patient with ER+ breast cancer consider: | |
|
|









0 Comments